← Universal Vision Biotechnology overview

Universal Vision Biotechnology vs Glaukos: why the prices moved differently

Weekly · monthly · quarterly news summaries, side by side in time

Universal Vision Biotechnology Co Ltd (3218.TWO)

Glaukos Corp (GKOS)

Q3 2026
▲3

Glaukos Surges on iDose TR and Epioxa Ramp, Raises Guidance

  • iDose TR and Epioxa drive record revenue and raised guidance Glaukos reported Q2 revenue of $185.6 million, up 50% year over year, with U.S. glaucoma revenue up 64% to $118.5 million and iDose TR sales reaching about $74 million. Management raised 2026 revenue guidance to $680–$700 million, up from $620–$635 million, citing strong adoption of iDose TR and the Epioxa launch. This boosts investor confidence in the growth trajectory.

    This is the core fundamental driver behind the stock's surge and guidance raise.

  • Epioxa shows durable three-year efficacy in keratoconus Glaukos reported positive three-year Phase 3 extension data for Epioxa, showing lasting visual gains and no serious safety issues in keratoconus patients after a single treatment. This supports the corneal health franchise as a second growth pillar alongside glaucoma, potentially expanding the market opportunity and reinforcing long-term revenue prospects.

    New clinical data validates a key growth product and supports the investment thesis.

  • iDose TR plus cataract surgery cuts eye pressure significantly A Phase 4 trial showed iDose TR combined with cataract surgery reduced intraocular pressure by 11.1 mmHg at three months, beating cataract surgery alone by 3.6 mmHg, with a favorable safety profile. This expands the potential use of iDose TR to a large cataract surgery population, opening a new avenue for adoption and revenue growth.

    New clinical evidence broadens the addressable market for the flagship product.

  • Retinal pipeline expansion via RevOpsis license, but stock dipped Glaukos licensed RO-104, a tri-specific biologic for retinal diseases, and gained exclusive rights to the RevMod platform to develop up to four more candidates. While this expands the long-term pipeline, the stock fell 6.3% on the news, possibly due to undisclosed financial terms or investor preference for nearer-term catalysts.

    New strategic move with mixed market reaction, relevant to future growth but not immediate revenue.

September 2026
▲3

Glaukos Surges on iDose TR and Epioxa Ramp, Raises Guidance

  • iDose TR and Epioxa drive record revenue and raised guidance Glaukos reported Q2 revenue of $185.6 million, up 50% year over year, with U.S. glaucoma revenue up 64% to $118.5 million and iDose TR sales reaching about $74 million. Management raised 2026 revenue guidance to $680–$700 million, up from $620–$635 million, citing strong adoption of iDose TR and the Epioxa launch. This boosts investor confidence in the growth trajectory.

    This is the core fundamental driver behind the stock's surge and guidance raise.

  • Epioxa shows durable three-year efficacy in keratoconus Glaukos reported positive three-year Phase 3 extension data for Epioxa, showing lasting visual gains and no serious safety issues in keratoconus patients after a single treatment. This supports the corneal health franchise as a second growth pillar alongside glaucoma, potentially expanding the market opportunity and reinforcing long-term revenue prospects.

    New clinical data validates a key growth product and supports the investment thesis.

  • iDose TR plus cataract surgery cuts eye pressure significantly A Phase 4 trial showed iDose TR combined with cataract surgery reduced intraocular pressure by 11.1 mmHg at three months, beating cataract surgery alone by 3.6 mmHg, with a favorable safety profile. This expands the potential use of iDose TR to a large cataract surgery population, opening a new avenue for adoption and revenue growth.

    New clinical evidence broadens the addressable market for the flagship product.

  • Retinal pipeline expansion via RevOpsis license, but stock dipped Glaukos licensed RO-104, a tri-specific biologic for retinal diseases, and gained exclusive rights to the RevMod platform to develop up to four more candidates. While this expands the long-term pipeline, the stock fell 6.3% on the news, possibly due to undisclosed financial terms or investor preference for nearer-term catalysts.

    New strategic move with mixed market reaction, relevant to future growth but not immediate revenue.

Latest
▲3

Glaukos Surges on iDose TR and Epioxa Ramp, Raises Guidance

  • iDose TR and Epioxa drive record revenue and raised guidance Glaukos reported Q2 revenue of $185.6 million, up 50% year over year, with U.S. glaucoma revenue up 64% to $118.5 million and iDose TR sales reaching about $74 million. Management raised 2026 revenue guidance to $680–$700 million, up from $620–$635 million, citing strong adoption of iDose TR and the Epioxa launch. This boosts investor confidence in the growth trajectory.

    This is the core fundamental driver behind the stock's surge and guidance raise.

  • Epioxa shows durable three-year efficacy in keratoconus Glaukos reported positive three-year Phase 3 extension data for Epioxa, showing lasting visual gains and no serious safety issues in keratoconus patients after a single treatment. This supports the corneal health franchise as a second growth pillar alongside glaucoma, potentially expanding the market opportunity and reinforcing long-term revenue prospects.

    New clinical data validates a key growth product and supports the investment thesis.

  • iDose TR plus cataract surgery cuts eye pressure significantly A Phase 4 trial showed iDose TR combined with cataract surgery reduced intraocular pressure by 11.1 mmHg at three months, beating cataract surgery alone by 3.6 mmHg, with a favorable safety profile. This expands the potential use of iDose TR to a large cataract surgery population, opening a new avenue for adoption and revenue growth.

    New clinical evidence broadens the addressable market for the flagship product.

  • Retinal pipeline expansion via RevOpsis license, but stock dipped Glaukos licensed RO-104, a tri-specific biologic for retinal diseases, and gained exclusive rights to the RevMod platform to develop up to four more candidates. While this expands the long-term pipeline, the stock fell 6.3% on the news, possibly due to undisclosed financial terms or investor preference for nearer-term catalysts.

    New strategic move with mixed market reaction, relevant to future growth but not immediate revenue.